Next Bio/Pharma focus:
1.$Altimmune(ALT)$
Obesity candidate pemvidutide: Perseverance of lean mass during weight loss, potential buyout target, gamma squeeze.
2. $SELLAS Life Sciences(SLS)$
SLS009 pipeline (target acute myeloid leukemia) increased market awareness.
Other than that, we’ve been adding every dip of the following:
Nebius, Sable Offshore, VOO, Tesla, Nixxy inc.
As I said before, The rally to the ATH(blowoff top) has begun.
Not financial advice.